Computed tomography/magnetic resonance based volume changes of the primary tumour in patients with prostate cancer with or without androgen deprivation.

Plain-language guide to PMID 11054523 (2000): randomized controlled trial of Antineoplastic Agents, Hormonal in 13 patients.

Key Facts

PMID: 11054523
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Year: 2000
Study type: Randomized Controlled Trial
Authors: Lilleby W et al. (6 authors)
DOI: 10.1016/s0167-8140(00)00219-x

What This Study Did, in Plain Language

What Was Tested

Researchers studied Antineoplastic Agents, Hormonal in this randomized controlled trial publication.

To evaluate changes of the volume of the cancerous prostatic gland during androgen deprivation (AD) started immediately after diagnosis (IAD).

Hypothetically, these data would assist the radiotherapist to determine the appropriate duration of pre-radiotherapy downsizing neoadjuvant luteinizing hormone releasing hormone (LHRH) treatment.

METHODS AND MATERIALS Thirteen patients in the IAD cohort and 13 patients in the DAD group, all with T1-3pN1-2M0 prostate cancer, had regular computed tomography/magnetic resonance (CT/MR) examinations during the 1st year after randomization within the EORTC-GU trial 30846.

Who Took Part

The abstract describes 13 patients taking part.

The age groups tagged for this paper are adults, middle-aged adults and older adults, men only.

How the Study Was Run

In design terms this was a randomized study.

The patients were allocated by chance, so the Antineoplastic Agents, Hormonal group and the comparison group should start out alike.

What Was Measured

Topics PubMed links to this paper include Androgens, Antineoplastic Agents, Hormonal, Confidence Intervals, Goserelin, Magnetic Resonance Imaging, Neoplasm Staging and Probability.

What This Means in Plain Language

The paper is a randomized study of Antineoplastic Agents, Hormonal in 13 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2000 (Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology), a journal based in Ireland.

More context: all human trials.

All human trials and studies

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.